ITP
Iron Triangle Partners Portfolio holdings
AUM
$632M
This Quarter Return
+3.24%
1 Year Return
+26.53%
3 Year Return
+134.07%
5 Year Return
+312.1%
10 Year Return
–
AUM
$572M
AUM Growth
+$572M
(-7.8%)
Cap. Flow
-$68.7M
Cap. Flow
% of AUM
-12.02%
Top 10 Holdings %
Top 10 Hldgs %
54.05%
Holding
34
New
9
Increased
5
Reduced
12
Closed
6
Top Buys
| 1 |
Charles River Laboratories
CRL
|
$39.8M |
| 2 |
Sanofi
SNY
|
$34.2M |
| 3 |
HCA Healthcare
HCA
|
$25.7M |
| 4 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$21.8M |
| 5 |
Insulet
PODD
|
$18.4M |
Top Sells
| 1 |
AbbVie
ABBV
|
$53.6M |
| 2 |
Humana
HUM
|
$31.5M |
| 3 |
AstraZeneca
AZN
|
$28.9M |
| 4 |
DexCom
DXCM
|
$28.2M |
| 5 |
Repligen
RGEN
|
$28.1M |
Sector Composition
| 1 | Healthcare | 98.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Charles River Laboratories
CRL
$8.04B
| $39.8M | 6.95% | +202,000 | New | +$39.8M |
|
2
Cigna
CI
$80.3B
| $39.7M | 6.94% | 143,010 +63,010 | +79% | +$17.5M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $37.8M | 6.6% | 355,601 +5,601 | +2% | +$595K |
|
|
4
Sanofi
SNY
$121B
| $34.2M | 5.98% | +900,000 | New | +$34.2M |
|
5
HealthEquity
HQY
$7.72B
| $29.6M | 5.17% | 440,000 -45,541 | -9% | -$3.06M |
|
6
Acadia Healthcare
ACHC
$2.12B
| $27.4M | 4.78% | 350,000 -200,000 | -36% | -$15.6M |
|
7
Boston Scientific
BSX
$156B
| $27.1M | 4.74% | 700,000 -300,000 | -30% | -$11.6M |
|
8
Guardant Health
GH
$8.41B
| $26.2M | 4.58% | 487,193 -503,375 | -51% | -$27.1M |
|
|
9
HCA Healthcare
HCA
$94.5B
| $25.7M | 4.5% | +140,000 | New | +$25.7M |
|
|
NARI
10
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $21.8M | 3.81% | +300,000 | New | +$21.8M |
|
11
Bio-Rad Laboratories Class A
BIO
$8.06B
| $20.9M | 3.65% | 50,000 -7,955 | -14% | -$3.32M |
|
|
12
Repligen
RGEN
$6.88B
| $18.7M | 3.27% | 100,000 -150,000 | -60% | -$28.1M |
|
|
13
Insulet
PODD
$23.9B
| $18.4M | 3.21% | +80,000 | New | +$18.4M |
|
|
CTLT
14
DELISTED
CATALENT, INC.
CTLT
| $18.1M | 3.16% | +250,000 | New | +$18.1M |
|
15
Inspire Medical Systems
INSP
$2.77B
| $17.7M | 3.1% | 100,000 -13,938 | -12% | -$2.47M |
|
16
Establishment Labs
ESTA
$1.2B
| $17.6M | 3.08% | 322,278 -2,730 | -0.8% | -$149K |
|
17
Pacific Biosciences
PACB
$393M
| $17.4M | 3.04% | +3,000,000 | New | +$17.4M |
|
|
18
Humana
HUM
$36.5B
| $17M | 2.97% | 35,000 -65,000 | -65% | -$31.5M |
|
19
Sarepta Therapeutics
SRPT
$1.78B
| $16.6M | 2.9% | +150,000 | New | +$16.6M |
|
|
HZNP
20
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $16.4M | 2.87% | 265,076 +115,076 | +77% | +$7.12M |
|
21
Alnylam Pharmaceuticals
ALNY
$58.5B
| $16M | 2.8% | +80,000 | New | +$16M |
|
22
Icon
ICLR
$13.8B
| $15.4M | 2.69% | 83,798 -76,202 | -48% | -$14M |
|
23
908 Devices
MASS
$226M
| $14.8M | 2.59% | 900,000 +50,000 | +6% | +$823K |
|
24
Surgery Partners
SGRY
$2.91B
| $12.9M | 2.25% | 550,000 +281,824 | +105% | +$6.59M |
|
|
25
DexCom
DXCM
$29.5B
| $12.1M | 2.11% | 150,000 -350,000 | -70% | -$28.2M |
|